ClinicalTrials.gg

Alkermes, Inc. clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 93 studies whose lead sponsor is Alkermes, Inc. or one of 2 companies grouped under it. 8 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 17, 2026.

Our grouping of 3 registry names, not the registry’s. See them and correct one ↓

Compare Alkermes with Takeda and Jazz Pharmaceuticals →

Pipeline: 2 programs

Each counted once: 2 with a study Alkermes, Inc. leads registered in the last two years.

  • Phase 2
  • Phase 3

The 1 phase-3 program — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Alkermes, Inc.’s own registered studies; Alkermes, Inc.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Alkermes, Inc.’s studies test, most open studies first — 14 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 4 more

Coming up

6 of Alkermes, Inc.’s studies under way reach primary completion within a year, 4 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 1N’26
  2. D
  3. J’27
  4. F
  5. M
  6. A
  7. 2M
  8. 1J
  9. 1J
  10. A
  11. 1S
  12. O
  13. N

Add all 6 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 18, 2026.

All 93 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now89%Recruiting 7 · Enrolling by invitation 1
  • Under way, not recruiting22%
  • Completed7581%
  • Stopped early78%
  • Status unknown or other11%

Phase

  • Phase 338
  • Phase 128
  • Phase 224
  • Phase 43
  • Early Phase 11

Where

  • United States80
  • Australia16
  • Spain13
  • Canada13
  • Korea, Republic of12
  • Italy11

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 1115
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 526

By the year each study started; 6 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Alkermes, Inc..

  • Alkermes, Inc.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    83 studies
  • Mural Oncology, Inc
    Divested — left Alkermes, Inc., Nov 15, 2023 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • Avadel
    Acquired — became part of Alkermes, Inc., Feb 12, 2026 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    4 studies →

Focus areas

Conditions Alkermes, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 93. Browse all 93 →